Yani Liu

Dr. Yani Liu

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
YLYani Liu
Yani Liu
ZLZongtao Liu
Zongtao Liu
KWKewei Wang
Kewei Wang
Anoctamin 1 (ANO1) or TMEM16A gene encodes a member of Ca2+ activated Cl– channels (CaCCs) that are critical for physiological functions, such as epithelial secretion, smooth muscle contraction and sensory signal transduction. The attraction and interest in ANO1/TMEM16A arise from a decade long investigations that abnormal expression or dysfunction of ANO1 is involved in many pathological phenotypes and diseases, including asthma, neuropathic pain, hypertension and cancer. However, the lack of specific modulators of ANO1 has impeded the efforts to validate ANO1 as a therapeutic target. This review focuses on the recent progress made in understanding of the pathophysiological functions of CaCC ANO1 and the current modulators used as pharmacological tools, hopefully illustrating a broad spectrum of ANO1 channelopathy and a path forward for this target validation.

1 September 2019 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
YLYani Liu
Yani Liu
HZHuiran Zhang
Huiran Zhang
HMHongchao Men
Hongchao Men
YDYuwei Du
Yuwei Du
ZXZiqian Xiao
Ziqian Xiao
HZHailin Zhang
Hailin Zhang
The swelling-activated chloride current ( ICl,swell) is induced when a cell swells and plays a central role in maintaining cell volume in response to osmotic stress. The major contributor of ICl,swell is the volume-regulated anion channel (VRAC). Leucine-rich repeat containing 8A (LRRC8A; SWELL1) was recently identified as an essential component of VRAC, but the mechanisms of VRAC activation are still largely unknown; moreover, other Cl− channels, such as anoctamin 1 (ANO1), were also suggested to contribute to ICl,swell. In this present study, we investigated the roles of LRRC8A and ANO1 in activation of ICl,swell; we also explored the role of intracellular Ca2+ in ICl,swell activation. We used a CRISPR/Cas9 gene editing approach, electrophysiology, live fluorescent imaging, selective pharmacology, and other approaches to show that both LRRC8A and ANO1 can be activated by cell swelling in HEK293 cells. Yet, both channels contribute biophysically and pharmacologically distinct components to ICl,swell, with LRRC8A being the major component. Cell swelling induced oscillatory Ca2+ transients, and these Ca2+ signals were required to activate both the LRRC8A- and ANO1-dependent components of ICl,swell. Both ICl,swell components required localized rather than global Ca2+ for activation. Interestingly, while intracellular Ca2+ was necessary and sufficient to activate ANO1, it was necessary but not sufficient to activate LRRC8A-mediated currents. Finally, Ca2+ transients linked to the ICl,swell activation were mediated by the G protein-coupled receptor-independent PLC isoforms.

26 February 2022 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
YYYufen Yan
Yufen Yan
XDXiaoyan Ding
Xiaoyan Ding
CHChunhua Han
Chunhua Han
JGJianjun Gao
Jianjun Gao
ZLZongtao Liu
Zongtao Liu
KWKewei Wang
Kewei Wang

8 June 2021 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
HNHe-Ling Niu
He-Ling Niu
YLYani Liu
Yani Liu
DXDeng-Qi Xue
Deng-Qi Xue
LDLi-Ying Dong
Li-Ying Dong
HLHui-Jie Liu
Hui-Jie Liu
KWKewei Wang
Kewei Wang

20 January 2023 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
JGJian Gao
Jian Gao
HYHao Yin
Hao Yin
YDYanqun Dong
Yanqun Dong
XWXintong Wang
Xintong Wang
YLYani Liu
Yani Liu
KWKewei Wang
Kewei Wang
A uricosuric drug benzbromarone, widely used for treatment of gout, hyperpolarizes the membrane potential of airway smooth muscle cells, but how it works remains unknown. Here we show a novel role of benzbromarone in activation of large conductance calcium-activated K+ channels. Benzbromarone results in dose-dependent activation of macroscopic BK currents about 1.7 to 14.5 folds with an EC50 of 111 μM and shifts the voltage-dependent channel activation to a more hyperpolarizing direction about 10 to 54 mV in whole-cell patch clamp recordings. In single-channel recordings, benzbromarone decreases single BKα channel closed dwell time and increases the channel open probability. Co-expressing β1 subunit also enhances BK activation by benzbromarone with an EC50 of 67 μM and a leftward shift of G-V curve about 44 to 138 mV. Site-directed mutagenesis reveals that a motif of three amino acids 329RKK331 in the cytoplasmic linker between S6 and C-terminal RCK gating ring mediates the pharmacological activation of BK channels by benzbromarone. Further ex vivo assay shows that benzbromarone causes reduction of tracheal strip contraction. Taken together, our findings demonstrate that uricosuric benzbromarone activates BK channels through molecular mechanism of action involving the channel RKK motif of S6-RCK linker. Pharmacological activation of BK channel by benzbromarone causes reduction of tracheal strip contraction, holding a repurposing potential for asthma and pulmonary arterial hypertension or BK channelopathies. Significance Statement We describe a novel role of uricosuric agent benzbromarone in BK channel activation and relaxation of airway smooth muscle contraction. In this study, we find that benzbromarone is an activator of the large-conductance Ca2+- and voltage-activated K+ channel (BK channel) that serves numerous cellular functions including control of smooth muscle contraction. Pharmacological activation of BK channel by an FDA approved drug benzbromarone may hold repurposing potential for treatment of asthma and pulmonary arterial hypertension or BK channeopathies.

25 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
LDLiying Dong
Liying Dong
QZQiqi Zhou
Qiqi Zhou
QLQianqian Liang
Qianqian Liang
ZQZhen Qiao
Zhen Qiao
YLYani Liu
Yani Liu
KWKewei Wang
Kewei Wang
Transient receptor potential vanilloid 1 (TRPV1) is a non-selective cation channel, predominantly expressed in a subset of peripheral sensory neurons for pain signaling. Topical application of agonist capsaicin for desensitizing TRPV1 currents has been approved for relief of chronic pain. However, the potent TRPV1 capsaicin is not ingestible and even topical capsaicin causes common side effects such as skin irritation, swelling, erythema and pruritus, suggesting that a mild TRPV1 agonist might be helpful for reducing side effects while reliving pain. In this study, we reported on a partial and selective TRPV1 agonist 4-(5-chloropyridin-2-yl)-N-(1H-indazol-6-yl)piperazine-1-carboxamide named CPIPC that was modified based on targeting the residue Arg557, important for conversion between the channel antagonism and agonism. Whole-cell patch clamp recordings indicated a concentration-dependent activation of TRPV1 currents by CPIPC with an EC50 of 1.56 ± 0.13 μM. The maximum efficacy of CPIPC (30 μM) was about 60% of saturated capsaicin (10 μM). Repetitive additions of CPIPC caused TRPV1 current desensitization in both TRPV1-expressing HEK293 cells and dorsal root ganglion (DRG) sensory neurons. Oral administration of CPIPC dose-dependently alleviated inflammatory pain in mice. Further site-directed mutagenesis combined with molecular docking revealed that residue Arg557 is critical for TRPV1 activation by CPIPC. Taken together, we identified a novel partial and selective TRPV1 agonist CPIPC that exhibits antinociceptive activity in mice.